Saum Ghodoussipour, MD, urologic oncologist, director, Bladder and Urothelial Cancer Program, Rutgers Cancer Institute of New Jersey, assistant professor of surgery, Rutgers Robert Wood Johnson (RWJ) Medical School, RWJ University Hospital, discusses ongoing trials in renal cell carcinoma (RCC) and prostate cancer.

Although patients with metastatic RCC and prostate cancer are typically managed with systemic therapies, several ongoing clinical trials are evaluating the role of cytoreductive surgery in this setting, Ghodoussipour says. Early evidence suggests that cytoreductive surgery may have utility in the metastatic setting for these patient populations, Ghodoussipour explains.

Regarding RCC, the phase 2 Cyto-KIK trial (NCT04322955) is evaluating the utility of neoadjuvant and adjuvant nivolumab (Opdivo) plus cabozantinib (Cabometyx) with cytoreductive surgery in patients with metastatic RCC, Ghodoussipour says. In prostate cancer, the phase 2 SIMCAP study (NCT03456843) is examining the role of radical prostatectomy plus antiandrogen agents with or without docetaxel in men with newly diagnosed metastatic prostate cancer. The results of the study may inform whether it is possible to prolong survival and delay progression of disease with surgery and best systemic therapy, Ghodoussipour concludes.

Videos

Saum Ghodoussipour, MD, discusses ongoing trials in renal cell carcinoma and prostate cancer. 


Dr. Ghodoussipour on Trials of Cytoreductive Surgery in Metastatic RCC and Prostate Cancer 

Saum Ghodoussipour, MD, urologic oncologist, director, Bladder and Urothelial Cancer Program, Rutgers Cancer Institute of New Jersey, assistant professor of surgery, Rutgers Robert Wood Johnson Medical School, attending, Robert Wood Johnson University Hospital, discusses ongoing trials in non–muscle invasive bladder cancer (NMIBC). 

Several interesting studies are taking place currently in NMIBC, which is how most patients with bladder cancer present, Ghodoussipour says. The standard of care currently is intravesical therapy with Bacillus Calmette-Guérin (BCG), the vaccine for tuberculosis, Ghodoussipour adds. The therapy stimulates a local immune response in this patient population; however, almost half of patients do not derive a response resulting in the need for additional invasive treatments, Ghodoussipour explains.

Clinicians are studying BCG in combination with the checkpoint inhibitor pembrolizumab (Keytruda), with the goal of improving treatment after prior failure with BCG, Ghodoussipour continues. Moreover, clinicians are attempting to give BCG and pembrolizumab in the frontline setting for patients with treatment-naïve NMIBC to see whether it will improve outcomes for patients, Ghodoussipour concludes.

Saum Ghodoussipour, MD, discusses ongoing trials in non–muscle invasive bladder cancer. 

Saum Ghodoussipour, MD

Articles

Dr. Ghodoussipour on Trials of Cytoreductive Surgery in Metastatic RCC and Prostate Cancer

Dr. Ghodoussipour on Ongoing Trials in Non–Muscle Invasive Bladder Cancer